The 6th edition of the International HBV Cure Workshop featured the world's most prominent and distinguished speakers that discussed the most current and trending issues in the field.
Meeting category
Date(s)
6 Nov 2019
Location
Toronto,
Canada
Organizer
International Workshop on HBV Cure 2019
Related Enduring Materials
Enduring Materials
Program
Wednesday, 6 November 2019
- 08:00
Harry Janssen, MD, PhD
08:00 EDT
Welcome
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada
Session 1: Review of Nucleoside analogue Stopping studies -
Chairs
David Wong
-
Marion Peters, MA
University of California, USA
08:10 EDT
Stopping Nucleos(t)ide Analogues: Clinical outcomes of HBs Loss, retreatment and flares
08:25 EDT
Virological biomarkers in patients stopping Nucs
08:40 EDT
Immunological response after stopping Nucs
Session 2: New Endpoints and Biomarkers -
Harry Janssen, MD, PhD
Chairs
Robert Gish
Robert G. Gish Consultants LLC
09:20 EDT
Review of the FDA/EMA HBV Endpoints Meeting
09:35 EDT
Are HBcrAg, HBV RNA and anti-HBc Viable Biomarkers
09:50 EDT
Are ALT Flares Associated with Improved Virological Clearance
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada
Session 3: How to make immunology curative -
Chairs
Georg Lauer
-
10:55 EDT
Restoration of B cell Antibody Production in Chronic HBV patients
11:10 EDT
Using FNAB to Investigate Intrahepatic Immunology
11:25 EDT
Springbank RIG-I Agonist (Inarigivir)
Cheleas MacFarlane
Springbank Pharmaceuticals, Inc.
11:35 EDT
Gilead TLR8 agonist (GS-9688)
Session 4: Update on Viral Targets for HBV/HDV Therapy -
Chairs
Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)
Victorian Infectious Diseases Reference Laboratory
Raymond Schinazi, PhD, DSc
Emory University Center for AIDS Research (CFAR), USA
13:30 EDT
Mechanisms of cccDNA Maintenance and progress on Measurement
13:45 EDT
Capsid inhibitor/cccDNA Inhibitor - Roche
13:55 EDT
Elimination of Residual HBV Replication and Prevention of cccDNA Generation with the Combination of NrtI and Core Inhibitor
14:25 EDT
MyrB + IFN effect on HBV & HDV
Stefan Urban
Heidelberg University Hospital
Session 5: New Drug Combinations and Study Design -
Harry Janssen, MD, PhD
Chairs
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada
15:45 EDT
FDA Guidance on New Combinations
16:00 EDT
Hypothesized Synergies in new cobmination treatment beyond nucs
16:15 EDT
Study Design with New Combinations
17:15 EDT
Closure of workshop
Overview
Welcome
Thank you for joining us at the International HBV Cure Workshop 2019, which took place on 6 November 2019 in Toronto, Canada. Since 2014, the HBV Cure Workshop has been a scientific platform that acts as a catalyst to accelerate the progress for achieving a cure.
Make sure you are subscribed to our newsletter for more information about the HBV Cure Workshop.
Background
More than 250 million people are chronically infected with hepatitis B (HBV) around the globe. The purpose of the program is to inform the participants about the developments in the possibilities to find a cure for HBV. The meeting will be highly interactive with input from experts out of the arena of basic, translational and clinical HBV research.
The field of HBV treatment is undergoing major changes and is on the verge of a paradigm shift. The many new treatment options that are becoming available are providing great hopes for decreasing the burden of the disease, simplifying treatment and ultimately curing and eradicating HBV infection.
In order to optimize curative treatment for HBV, outstanding speakers from around the globe will share the newest therapeutic options for viral hepatitis and experts will discuss the path forward to cure this deadly disease, leading to liver cirrhosis and liver cancer. Questions on which end points to use in therapeutic trials and how to combine different agents targeting the virus and/or immune system will be extensively discussed.
This workshop also brings together global inter-disciplinary experts to provide a framework for how academia and industry should could collaborate to achieve the goal of curing hepatitis B.
Practical Information
Language
The official conference language was English.
Disclaimer
This workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this workshop, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this workshop. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the workshop.
Liability and Insurance
By registering for the conference participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Meeting Venue
DoubleTree by Hilton Hotel Toronto Downtown
108 Chestnut St
Toronto, ON
M5G 1R3, Canada
108 Chestnut St
Toronto, ON
M5G 1R3, Canada
Photographs, Audio, and Video Recording
Photographs as well as audio and video recordings are not permitted at the official meeting sessions. Only the official medical writer, appointed by the organization, may make recordings. All presentations that we were granted permission for, will be posted on the workshop website (under Workshop Materials) as soon as possible after the workshop is finished, provided the speaker has given permission to do so.
Committees
Organizing Committee
The members of the Organizing Committee (OC) discuss, on a frequent basis, the scientific program of the workshop, identify interesting topics and candidate speakers.
Support
Sliver Level
Bronze Level
Contributors
Friend Level
Workshop Partner
Official Media Partners
Endorsers
Endorsers
Language
Related Programs
